HealthQuill Merck & Co
Merck & Co will buy Terns Pharmaceuticals, Inc., a clinical-stage oncology company, for $6.7 billion to pocket an investigational drug to treat a type of blood cancer, according to a statement.
Drugs Health Pharma

Merck to buy Terns for $6.7 billion as Keytruda drug patent loss looms

Merck & Co will buy Terns Pharmaceuticals, Inc., a clinical-stage oncology company, for $6.7 billion to pocket an investigational drug to treat a.

Read More
The US drug regulator, the Food and Drug Administration, has approved Merck & Co.’s new formulation of its cancer drug Keytruda that can be administered under the skin for adults.
Drugs Health Pharma

US approves Merck’s skin injectable version of cancer drug Keytruda

The US drug regulator, the Food and Drug Administration, has approved Merck & Co.’s new formulation of its cancer drug Keytruda that can.

Read More
Merck & Co. will acquire UK-based Verona Pharma Plc for about $10 billion to gain access to a respiratory drug approved by the US regulator, according to a statement from Merck.
Drugs Health Pharma

Merck to acquire Verona Pharma for $10 billion to net respiratory drug 

HQ Team July 9, 2025: Merck & Co. will acquire UK-based Verona Pharma Plc for about $10 billion and gain access to a.

Read More
Merck & Co.’s two oral cholesterol pill trials — one mid-stage and the other end-stage — showed “positive top-line results” on the efficacy and safety of the treatment in adults, according to the company.
Drugs Health Pharma

Merck’s oral pill for bad cholesterol shows ‘positive’ data during trials

HQ Team June 10, 2025: Merck & Co.’s two oral cholesterol pill trials — one mid-stage and the other end-stage — showed “positive.

Read More
The Food and Drug Administration has approved Merck & Co. Inc.’s jab for preventing respiratory syncytial virus (RSV) in infants up to one year of age for the first RSV season.
Drugs Health Pharma

Merck & Co.’s RSV injection for infants gets nod from US drug regulator

HQ Team June 10, 2025: The Food and Drug Administration has approved Merck & Co. Inc.’s jab for preventing respiratory syncytial virus (RSV).

Read More
Merck & Co., Inc.’s drug Keytruda, along with Gilead Sciences Inc.'s antibody-drug conjugate, cut the risk of an aggressive breast cancer advancement and death by 35% during an end-stage trial.
Drugs Health Pharma

Merck, Gilead’s drug for breast cancer cuts progression risk by 35 per cent

HQ Team June 1, 2025: Merck & Co., Inc.’s drug Keytruda, along with Gilead Sciences Inc.’s antibody-drug conjugate, cut the risk of an.

Read More
Merck & Co. got approval from the US Food and Drug Administration for a pill to treat a rare type of tumour in adults and children aged above 12 years, according to a statement.
Drugs Health Pharma

Merck’s pill to treat rare type of tumour gets approval from US regulator

HQ Team May 15, 2025: Merck & Co. got approval from the US Food and Drug Administration for a pill to treat a.

Read More
Austria’s Cyprumed GmbH has announced a license and option agreement with Merck & Co., to develop oral formulations of the US-based company’s peptides for an upfront payment of $493 million.
Drugs Health Medical

Austria’s Cyprumed in $493 million pact with Merck to develop peptides

HQ Team April 17, 2025: Austria’s Cyprumed GmbH has announced a license and option agreement with Merck & Co., to develop oral formulations.

Read More
Merck & Co., Inc. has bought global rights for an experimental oral drug to treat heart diseases from China’s Jiangsu Hengrui Pharmaceuticals Co., Ltd. in a $2 billion deal.
Drugs Health Pharma

Merck signs $2b licensing deal with Jiangsu Hengrui for heart disease drug

HQ Team March 25, 2025: Merck & Co., Inc. has bought global rights for an experimental oral drug to treat heart diseases from.

Read More
China has approved Merck & Co.’s human papillomavirus vaccine for males between nine and 26 years amid a fall in sales for the jab among women in the world’s most populous country, according to a company statement.
Drugs Health Medical

China approves Merck’s human papillomavirus jab for use in males 

China has approved Merck & Co.’s human papillomavirus vaccine for males between nine and 26 years amid a fall in sales for the.

Read More